Nexscient Financials
This page shows Nexscient (NXNT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Pre-revenue operations are being sustained by asset monetization and rising liabilities, not by cash generated from customers.
Cash rose to$100K in FY2025 from$76K in FY2024, but that improvement did not come from the core business because operating cash flow was negative while investing cash flow was positive. Meanwhile, equity swung from$82K to-$265K as liabilities overtook assets, so short-term liquidity and overall solvency moved in opposite directions.
With no revenue and FY2025 operating cash flow of
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Nexscient's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nexscient carries a low D/E ratio of -2.14, meaning only $-2.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.
Nexscient's current ratio of 2.47 indicates adequate short-term liquidity, earning a score of 46/100. The company can meet its near-term obligations, though with limited headroom.
Nexscient passes 1 of 9 financial strength tests. 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Nexscient generates $0.77 in operating cash flow (-$408K OCF vs -$530K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Nexscient generated $0 in revenue in fiscal year 2025.
Nexscient reported -$530K in net income in fiscal year 2025.
Cash & Balance Sheet
Nexscient held $100K in cash against $0 in long-term debt as of fiscal year 2025.
Nexscient had 21M shares outstanding in fiscal year 2025. This represents an increase of 4.4% from the prior year.
Margins & Returns
Capital Allocation
Nexscient invested $97K in research and development in fiscal year 2025. This represents a decrease of 52.6% from the prior year.
NXNT Income Statement
| Metric | Q4'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $7K-33.3% | $11K0.0% | $11K | N/A | $0-100.0% | $10K-85.7% | $70K | N/A |
| SG&A Expenses | $108K-14.6% | $127K-12.1% | $144K | N/A | $115K-23.5% | $150K+159.2% | $58K | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $12K-2.2% | $12K-0.2% | $12K | N/A | -$20K | $0 | $0 | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$127K+14.9% | -$149K+10.5% | -$167K | N/A | -$135K+15.6% | -$160K-25.2% | -$128K | N/A |
| EPS (Diluted) | $-0.01 | N/A | N/A | N/A | $-0.010.0% | $-0.01 | N/A | N/A |
NXNT Balance Sheet
| Metric | Q4'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | N/A | $288K+22.1% | $235K-21.9% | $302K+66.8% | $181K+91.0% | $95K-48.4% | $184K+47.6% | $124K |
| Current Assets | N/A | $115K+16.4% | $99K-38.3% | $160K+360.6% | $35K-56.0% | $79K-51.7% | $163K+63.8% | $100K |
| Cash & Equivalents | N/A | $28K-51.7% | $59K-41.3% | $100K+370.0% | $21K-73.0% | $79K-47.8% | $151K+99.8% | $76K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | N/A | $784K+17.5% | $667K+17.8% | $566K+42.6% | $397K+32.2% | $300K+30.9% | $229K+438.8% | $43K |
| Current Liabilities | N/A | $486K+368.6% | $104K+59.7% | $65K+23.4% | $53K+92.5% | $27K-42.9% | $48K+32.1% | $36K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | N/A | -$496K-14.9% | -$432K-63.1% | -$265K-22.4% | -$216K-5.1% | -$206K-348.6% | -$46K-156.0% | $82K |
| Retained Earnings | N/A | -$1.9M-8.7% | -$1.7M-10.7% | -$1.6M-7.4% | -$1.5M-10.2% | -$1.3M-13.8% | -$1.2M-12.4% | -$1.0M |
NXNT Cash Flow Statement
| Metric | Q4'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$23K+42.0% | -$40K+55.8% | -$92K-123.7% | -$41K+61.1% | -$105K+33.2% | -$157K-50.8% | -$104K+27.4% | -$144K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$48K | N/A | N/A | $528K | N/A | N/A | N/A | $519K |
| Financing Cash Flow | $750K+7400.0% | $10K-80.0% | $50K+112.3% | -$408K-528.9% | $95K+11.8% | $85K-52.8% | $180K+138.4% | -$469K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NXNT Financial Ratios
| Metric | Q4'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | -52.0%+18.9pp | -70.9% | N/A | -74.6%+94.2pp | -168.8%-99.2pp | -69.5% | N/A |
| Current Ratio | N/A | 0.24-0.7 | 0.95-1.5 | 2.47+1.8 | 0.66-2.2 | 2.89-0.5 | 3.42+0.7 | 2.76 |
| Debt-to-Equity | N/A | -1.58-0.0 | -1.55+0.6 | -2.14-0.3 | -1.84-0.4 | -1.46+3.5 | -5.01-5.5 | 0.52 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$265K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Frequently Asked Questions
What is Nexscient's annual revenue?
Nexscient (NXNT) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Nexscient profitable?
No, Nexscient (NXNT) reported a net income of -$530K in fiscal year 2025.
What is Nexscient's operating cash flow?
Nexscient (NXNT) generated -$408K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nexscient's total assets?
Nexscient (NXNT) had $302K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Nexscient spend on research and development?
Nexscient (NXNT) invested $97K in research and development during fiscal year 2025.
What is Nexscient's current ratio?
Nexscient (NXNT) had a current ratio of 2.47 as of fiscal year 2025, which is generally considered healthy.
What is Nexscient's debt-to-equity ratio?
Nexscient (NXNT) had a debt-to-equity ratio of -2.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nexscient's return on assets (ROA)?
Nexscient (NXNT) had a return on assets of -175.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nexscient's cash runway?
Based on fiscal year 2025 data, Nexscient (NXNT) had $100K in cash against an annual operating cash burn of $408K. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Nexscient's debt-to-equity ratio negative or unusual?
Nexscient (NXNT) has negative shareholder equity of -$265K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Nexscient's Piotroski F-Score?
Nexscient (NXNT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nexscient's earnings high quality?
Nexscient (NXNT) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Nexscient?
Nexscient (NXNT) scores 23 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.